Overview

• McKesson Corp fiscal Q2 rev grows 10% yr/yr, slightly missing analyst expectations

• Adjusted EPS for fiscal Q2 beats consensus, rising 39% yr/yr

• Company raises fiscal 2026 adjusted EPS guidance, indicating confidence in growth strategy

Outlook

• McKesson raises fiscal 2026 adjusted EPS guidance to $38.35-$38.85, from the previous range of $38.05 to $38.55

• Company does not forecast GAAP earnings

• McKesson sees 16%-18% growth in fiscal 2026 adjusted EPS

Result Drivers

• NORTH AMERICAN PHARMACEUTICAL GROWTH - Revenue growth driven by increased prescription volumes from retail national account customers and specialty products

• ONCOLOGY & MULTISPECIALTY SEGMENT - Segment revenue increased 32% due to provider and specialty distribution growth and acquisitions

• ADJUSTED EPS DRIVERS - Increase driven by operational growth, net gains from investments, and lower tax rate

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for McKesson Corp is $856.50, about 1.7% above its November 4 closing price of $841.67

• The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)